The New England Journal of Medicine: Compassionate Use of Remdesivir for Patients with Severe Covid-19
Remdesivir, a nucleotide analogue prodrug that inhibits viral RNA polymerases, has shown in vitro activity against SARS-CoV-2. METHODS We provided remdesivir on a compassionate-use basis to patients hospitalized with Covid-19, the illness caused by infection with SARS-CoV-2. Patients were those with confirmed SARS-CoV-2 infection who had an oxygen saturation of 94% or less while they were breathing ambient air or who were receiving oxygen support. Patients received a 10-day course of remdesivir, consisting of 200 mg administered intravenously on day 1, followed by 100 mg daily for the remaining 9 days of treatment. This report is based on data from patients who received remdesivir during the period from January 25, 2020, through March 7, 2020, and have clinical data for at least 1 subsequent day. RESULTS Of the 61 patients who received at least one dose of remdesivir, data from 8 could not be analyzed (including 7 patients with no post-treatment data and 1 with a dosing error). Of the 53 patients whose data were analyzed, 22 were in the United States, 22 in Europe or Canada, and 9 in Japan. At baseline, 30 patients (57%) were receiving mechanical ventilation and 4 (8%) were receiving extracorporeal membrane oxygenation. During a median follow-up of 18 days, 36 patients (68%) had an improvement in oxygen-support class, including 17 of 30 patients (57%) receiving mechanical ventilation who were extubated. A total of 25 patients (47%) were discharged, and 7 patients (13%) died; mortality was 18% (6 of 34) among patients receiving invasive ventilation and 5% (1 of 19) among those not receiving invasive ventilation. CONCLUSIONS In this cohort of patients hospitalized for severe Covid-19 who were treated with compassionate-use remdesivir, clinical improvement was observed in 36 of 53 patients (68%). Measurement of efficacy will require ongoing randomized, placebo-controlled trials of remdesivir therapy. To read more-https://www.nejm.org/doi/10.1056/NEJMoa2007016
Informative post.
Helping
Helpful Post
It means Remdesivir is inefective
Cases that would interest you
- Login to View the image
PATHOPHYSIOLOGY OF AKI IN COVID- 19 PATIENTS. AKI appears to involve a complex process driven by virus-mediated injury, cytokine storm, AngII pathway activation, dysregulation of complement, hypercoagulation, and microangiopathy interacting with common and known risk factors for AKI . There is paucity of data regarding clinical and laboratory characteristics of AKI in patients with COVID-19. We urge that further studies describing and analyzing the clinical course of patients with COVID-19 include appropriate indices of kidney function and diagnosis of AKI in their analyses, including kidney injury markers, urine microscopy, quantified urine protein, urine output, and urine electrolytes. Markers of macrophage activation, coagulation, microangiopathy, and complement activation, as well as kidney imaging and need for KRT (with relevant details), are important data needed to further our understanding of AKI pathophysiology associated with COVID-19. Rates of reversibility of, or partial improvement in, kidney function and any kidney biopsy results (including immunofluorescence and electron microscopy) should be reported. In the rush to report medical complications of COVID-19, we are missing valuable clinical information. Speculation about specific interventions would not be appropriate until we obtain appropriate information. We advocate for a complete and standardized appraisal of the clinical and laboratory picture so that preventative and therapeutic strategies for AKI can be appropriately designed and implemented.
Dr. Parveen Yograj13 Likes15 Answers - Login to View the image
30 year old male, 10 day history of diarrhoea and reduced oral intake, presented with lethargy and ongoing abdominal cramps. No respiratory symptoms, but O2 sats noted to be on the lower side, exertional O2 sats dropped to 86%. No past medical history of note, normal white cell count, not lymphopenic, urea 18.9 mmol/L, creatinine: 489 µmol/L, amylase 600 (30-118), ALT: 65, CRP: 100, Trop I 267 (0-46). Chest X-ray as shown. What do you think the patient is suffered from?
Dr. Somi Suyal2 Likes18 Answers - Login to View the image
41 year old male presents to the ED with SOB x5 days. He was in contact with a COVID+ patient. He reports fever highest 102.3. States he has body aches and chills. Denies cough or sore throat. Places on 6L/min via NC and sats increased to 91%. History of Hypertension Hypothyroidism Morbid obesity Prediabetes. what do you suggest?
Dr. Narendra Kumar5 Likes17 Answers - Login to View the image
81 years old male, known COPD, presents with high grade fever, cough n SOB for last 6 days. His CRP is normal. D dimer, FERRITIN awaited. Anaemia present otherwise normal hemogram. Chest auscultation revealed bilateral expiratory rhonchi n RT LZ CREPITATIONS. Spo2 95% on air. Normal Temperature, BP n Pulse. His SARS COV 2 RT PCR came positive. Kindly discuss further management plan for this patient.
Dr. Viral Patel20 Likes17 Answers - Login to View the image
AYUSH System approach in COVID-19 by AYUSH Ministry Source-https://www.ayush.gov.in/docs/125.pdf
Dr. Pushker Mehra29 Likes19 Answers
11 Likes